Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15 2023 - 8:00AM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of injectable
biologics to selectively engage and modulate disease-specific T
cells directly within the patient’s body, announced today the
presentation of a poster at the American Society of Clinical
Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in
Chicago, IL.
The poster will highlight the company’s lead clinical drug
candidate from the CUE-100 series of interleukin 2 (IL-2)-based
biologics, CUE-101, for the treatment of patients with human
papilloma virus (HPV16+) recurrent/metastatic head and neck
squamous cell carcinoma (R/M HNSCC) as a monotherapy and in
combination with pembrolizumab (KEYTRUDA®).
The Company will host an Investor Update call on Wednesday, June
14, 2023 to review and discuss the clinical progress and associated
data presented at ASCO on June 5. Call details will be issued prior
to the event.
Presentation
DetailsTitle: A
phase 1 dose-escalation and expansion study of CUE-101, a novel
HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in
combination with pembrolizumab in patients with
recurrent/metastatic HPV16+ head and neck cancer.Abstract
Number:
6013 Session: Head and
Neck CancerPoster Session Display Date and
Time: June 5, 2023, 1:15 PM-4:15 PM
CDTPresenter: Christine Chung, M.D., Moffit
Cancer CenterPoster Discussion Session Date and
Time: June 5, 2023, 4:30 PM-6:00 PM
CDTDiscussant: Erminia Massarelli, M.D.,
Ph.D., City of Hope Comprehensive Cancer CenterThe poster will be
available in the Investor & Media section of the Company’s
website at www.cuebiopharma.com under Scientific
Publications and Presentations, following the
presentation.
About Cue BiopharmaCue Biopharma, a
clinical-stage biopharmaceutical company, is developing a novel
class of injectable biologics to selectively engage and modulate
disease-specific T cells directly within the patient’s body. The
company’s proprietary platform, Immuno-STAT™ (Selective
Targeting and Alteration of T cells) and biologics are
designed to harness the body’s intrinsic immune system as T cell
engagers without the need for ex vivo manipulation or broad
systemic modulation.
Headquartered in Boston, Massachusetts, we are led by
an experienced management team and independent Board of Directors
with deep expertise in immunology and immuno-oncology as well as
the design and clinical development of protein biologics.
For more information please
visit www.cuebiopharma.com and follow us on Twitter
at https://twitter.com/CueBiopharma.
Investor ContactMarie CampinellSenior Director,
Corporate CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com
Media ContactMaya RomanchukLifeSci
Communicationsmromanchuk@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From Apr 2024 to May 2024
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From May 2023 to May 2024